Proud to announce new Part the Cloud investments: $11 million in 11 studies developing potential new treatments for Alzheimer’s and other diseases that cause dementia. This brings our total PTC investment to $90m+. More: bit.ly/3LtnYo1
ISTAART is monitoring the potential impact of the government shutdown on researchers & the dementia care community where funds & staffing capacity are critical.
Thanks to @alzassociation advocacy, NIH requested $187M increase in FY27. Bipartisan momentum in Congress is strong!
Proud to share the Alzheimer’s Association invested $112.2M in research activities over the last year — our largest single-year commitment. From gene therapy to #BrainHealth to risk reduction to AI, we’re funding bold boundary-pushing ideas. alz.org/research
#ENDALZ
#AAIC2025 following USPointer recipe with a morning fun run!
Today’s news from #AAIC25 marks a moment so many of us in the Alzheimer’s and dementia scientific community have long hoped for. We can now say with confidence that lifestyle interventions can protect brain health in diverse communities in the U.S.
📣Today is a turning point in what we know about brain health.
The results from the U.S. POINTER trial provide the rigorous data needed to say with confidence that healthy behaviors can meaningfully protect brain health across diverse populations in the U.S.
#AAIC25 alz.org/USPOINTERresults
“This is just the beginning,” @BillGates.bsky.social wrote in a new blog post. He’s right — Alzheimer’s and dementia research has more momentum than ever before, but now we need to go faster, earlier and bolder. That’s what @ALZAssocation’s Part the Cloud is all about.
Congratulations to the recipients of the @alzassociation Part the Cloud Gene Targeting Challenge. This funding program is focused on gene editing, with the aim of developing potential therapies that change the expression of a gene at some level. bit.ly/4l8yEVx
The myths and fabrications persistently shared by the Health and Human Services Secretary aren’t just disappointing – they’re dangerous. See below for the facts and for our full statement in response to the Secretary’s comments.
It was a privilege to deliver one of the keynotes at today’s #CNDSymposium Day2 @iusm-medneuro.bsky.social alongside @elizabethhead.bsky.social @mariacarrilloalz.bsky.social. Congrats to @wilcocklab.bsky.social for the amazing 2 days of science 🤓💪🏼
@alzassociation.bsky.social CEO Dr Joanne Pike and the World Dementia Council rising chair is closing a fantastic day of discussions to accelerate innovation and deliver change! #ENDALZ
📣 Join the "The Basics: Glymphatic System – A Focus on the Role of Sleep" @istaart.bsky.social webinar to learn the fundamental mechanisms of the glymphatic system and the critical role of #sleep in its function. 🧠🧼💤
📆 Register alz-org.zoom.us/webinar/regi...
@claireandre.bsky.social #EndAlz
Observations from today’s confirmation hearing for the director of the NIH: 1. bipartisan support for addressing dementia was on full display & 2. harmful myths about Alzheimer’s research continue to persist and that needs to stop. Our full statement: bit.ly/4bql5Nv
So honored to be a part of this first symposium @IU @wilcocklab.bsky.social @malutansey.bsky.social to #ENDALZ
Join us this week in San Juan #PuertoRico for Human Amyloid Imaging Conference #HAI2025 😊 Excited to participate in a panel discussion on disparities in neuroimaging & AD research, organized by the ISTAART Neuroimaging PIA and Diversity & Disparities PIA (Prof Interest Area)🤩
What an incredible time period to be working on updated appropriate use criteria for amyloid and tau PET! Awesome group to work with...I learned so much🧠
alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
@alzassociation.bsky.social @snm-mi.bsky.social
🚨 ISTAART Voices is back! 🎉
Join us as we chat with scientists about their groundbreaking work from the Alzheimer’s & Dementia journal family.
Tune in on your favorite podcast platforms, or visit alz.org/ISTAARTpodcasts! 🎧
